pubrio
Sitryx

Sitryx

United Kingdom · Biotechnology Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Biotechnology Research

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.

Company Insights
Company Overview

2018

Founded

Biotechnology Research

Industry

United Kingdom

Location

3,438,645

Ranking

51 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Sitryx

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​